Invizyne Technologies Begins Trading on NASDAQ
Invizyne Technologies, a designer of cell-free, enzyme-based biomanufacturing systems, announced that its common shares will begin trading on the NASDAQ on November 13, 2024, at approximately 12:00pm EST under the ticker symbol 'IZTC'. The company specializes in producing commercially important molecules and chemicals for everyday life through their innovative biotechnology solutions.
Invizyne Technologies, un'azienda che progetta sistemi di biomanifattura a base enzimatica senza cellule, ha annunciato che le sue azioni ordinarie inizieranno a essere scambiate sul NASDAQ il 13 novembre 2024, alle ore 12:00 EST, con il simbolo ticker 'IZTC'. L'azienda si specializza nella produzione di molecole e sostanze chimiche di importanza commerciale per la vita quotidiana attraverso le sue soluzioni biotecnologiche innovative.
Invizyne Technologies, una empresa diseñadora de sistemas de biomanufactura basados en enzimas y libres de células, anunció que sus acciones ordinarias comenzarán a cotizar en el NASDAQ el 13 de noviembre de 2024, aproximadamente a las 12:00 p.m. EST bajo el símbolo de cotización 'IZTC'. La empresa se especializa en la producción de moléculas y productos químicos comercialmente importantes para la vida cotidiana a través de sus soluciones biotecnológicas innovadoras.
Invizyne Technologies는 세포가 필요 없는 효소 기반의 바이오 제조 시스템을 설계하는 회사로, 2024년 11월 13일 오후 12시 EST에 NASDAQ에서 'IZTC'라는 종목 코드로 일반 주식 거래를 시작한다고 발표했습니다. 이 회사는 혁신적인 생명공학 솔루션을 통해 일상생활에서 상업적으로 중요한 분자와 화학물질을 생산하는 데 전문화되어 있습니다.
Invizyne Technologies, une entreprise concevant des systèmes de biomanufacture sans cellule à base d'enzymes, a annoncé que ses actions ordinaires commenceront à être échangées sur le NASDAQ le 13 novembre 2024, à environ 12h00 EST sous le symbole boursier 'IZTC'. La société se spécialise dans la production de molécules et de produits chimiques d'importance commerciale pour la vie quotidienne grâce à ses solutions biotechnologiques innovantes.
Invizyne Technologies, ein Designer von zellfreien, enzymbasierten Bioproduktionssystemen, gab bekannt, dass seine Stammaktien am NASDAQ am 13. November 2024 около 12:00 Uhr EST unter dem Tickersymbol 'IZTC' gehandelt werden. Das Unternehmen ist auf die Produktion von kommerziell wichtigen Molekülen und Chemikalien für das tägliche Leben spezialisiert und bietet innovative biotechnologische Lösungen an.
- Uplisting to NASDAQ, providing increased visibility and potential access to larger investor base
- Successfully completed requirements for major exchange listing
- None.
Insights
The NASDAQ uplisting marks a significant milestone for Invizyne Technologies, potentially increasing visibility and access to institutional investors. However, without critical details about the listing method (IPO, direct listing, or SPAC merger) and financial terms, the immediate impact remains unclear. Cell-free enzyme-based biomanufacturing represents a growing market segment, but investors should note that the company's commercial success will depend heavily on its ability to scale production and secure partnerships. Trading on NASDAQ typically requires meeting strict listing requirements, including minimum stockholders' equity, market value and corporate governance standards, suggesting the company has achieved certain financial benchmarks.
Next Generation Synthetic Biology Company Will Trade Under Ticker Symbol "IZTC"
Monrovia, CA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Invizyne Technologies, Inc., a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, today announced that its common shares will begin trading on the NASDAQ today, November 13, 2024 at approximately 12:00pm EST under the ticker symbol “IZTC.”
About Invizyne Technologies, Inc.
Invizyne Technologies, Inc. is a cell-free enzyme-based biomanufacturing technology company headquartered in Monrovia, California. Invizyne is redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals, such as Active Pharmaceutical Ingredients (APIs), biofuels, food flavors, fragrances, cosmetics, etc. Management of Invizyne believes that its biomanufacturing platform, known as SimplePath™, will be a significant alternative to the current methods of chemical compound production, which are generally chemical synthesis, natural extraction, and synthetic biology. The objective for the SimplePath™ platform is to enable the efficient production of a diverse range of chemicals otherwise impossible to make, or very expensive to make. The SimplePath™ platform not only can maximize the value of these resources but also can contribute to the development of novel and renewable chemical compounds that hold the potential to open new markets and business opportunities.
For more information, please visit www.invizyne.com
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Invizyne's control. Invizyne's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors. The forward-looking statements included in this press release represent Invizyne's views as of the date of this press release. Invizyne anticipates that subsequent events and developments will cause its views to change. Invizyne undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Invizyne's views as of any date subsequent to the date of this press release.
Media contacts:
Lasse Görlitz, VP of Communications
(858) 319-7135
press@invizyne.com
Investor Relations Contact:
IR@invizyne.com
FAQ
When did Invizyne Technologies (IZTC) begin trading on NASDAQ?
What is Invizyne Technologies' (IZTC) NASDAQ ticker symbol?
What type of technology does Invizyne Technologies (IZTC) develop?
